VLDLR and familial hypercholesterolemia: Evolocumab selectively binds PCSK9, a secreted serine protease involved in cholesterol homeostasis, inducing low-density lipoprotein receptors (LDL-R) degradation, and according to this mechanism, it plays a key role in hypercholesterolemia, in platelet aggregation, and in the development of atherosclerotic plaque and aortic valve calcification (Qi), because it binds low-density lipoprotein receptor-related protein 1 (LRP1), apolipoprotein E receptor-2 (ApoER2), and very-low-density lipoprotein receptor (VLDL-R) [1].